ADVANCED THERAPY FOR ACUTE RESPIRATORY DISTRESS SYNDROME

急性呼吸窘迫综合征的先进疗法

• 批准号: 6403159
• 负责人: THOMAS E WISWELL
• 金额: $ 46.8万
• 依托单位: DISCOVERY LABORATORIES, INC.
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-09-30 至 2002-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6403159
• 关键词: adult respiratory distress syndrome; biotherapeutic agent; drug design /synthesis /production; drug screening /evaluation; laboratory rabbit; protease inhibitor; pulmonary surfactants; respiratory disorder chemotherapy; synthetic protein

DESCRIPTION (Adapted from the Investigator's Abstract): Acute respiratory distress syndrome is characterized clinically by markedly impaired gas exchange and pathologically by exudation of protein rich fluid into the airspaces and inflammatory pulmonary changes including loss of functional surfactant. Clinical trials of exogenous surfactant treatment of adult patients with ARDS have been disappointing, perhaps in part due to the fact that artificial surfactant is rapidly disabled by alveolar macrophage and neutrophil derived proteases and oxidants in the alveolar spaces. The PI and his colleagues propose Phase I and Phase II studies to assess the capacity of selected inhibitors of leukocyte proteases and oxidants to inhibit mediators of inflammatory response. Experimental therapeutic formulations containing these inhibitors will be developed and tested. The inhibitors to be tested will be selected based upon their efficacy in Phase I studies. Inhibitors will be mixed with Surfaxin (a mixture of artificial surfactant phospholipids and a mimic surfactant protein B) to treat the lungs of rabbits with pulmonary inflammatory injury. Additional work will be performed to establish manufacturability and commercial viability of advanced treatments for ARDS. All of these data will prepare for a clinical trial in which Surfaxin is combined with appropriate inhibitors of inflammation for use in patients with acute lung injury. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

描述（改编自调查员的摘要）：急性呼吸道 遇险综合征在临床上以明显受损的气体交换来表征 在病理上，富含蛋白质的液体进入空间和 炎症性肺部变化，包括功能性表面活性剂的丧失。 成人ARDS患者外源表面活性剂治疗的临床试验 令人失望的，也许部分是由于人为的事实 表面活性剂通过肺泡巨噬细胞和中性粒细胞迅速残疾 肺泡空间中的蛋白酶和氧化剂。 PI和他的同事 提出I期和第二阶段研究以评估选定的能力 白细胞蛋白酶和氧化剂的抑制剂可抑制介质的介体 炎症反应。实验性治疗配方包含这些 将开发和测试抑制剂。要测试的抑制剂将是 根据它们在第一阶段研究中的功效选择。抑制剂将混合 与表面素（人造表面活性剂磷脂的混合物和模拟物的混合物 表面活性剂蛋白b）用肺部炎症治疗兔子的肺 受伤。将进行其他工作以建立制造性和 高级治疗ARDS的商业生存能力。所有这些数据将 准备临床试验，在该试验中，表面素与适当的 炎症抑制剂用于急性肺损伤患者。 拟议的商业应用程序：不可用